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Artificial Intelligence for Unstructured 
Healthcare Data: Application to Coding of 
Patient Reporting of Adverse Drug Reactions
Louis Létinier1,2,3,*, Julien Jouganous3, Mehdi Benkebil4, Alicia Bel- Létoile3, Clément Goehrs3, Allison 
Singier1, Franck Rouby5,6, Clémence Lacroix5,6, Ghada Miremont1,2, Joëlle Micallef5,6, Francesco Salvo1,2 and 
Antoine Pariente1,2
Adverse drug reaction (ADR) reporting is a major component of drug safety monitoring; its input will, however, 
only be optimized if systems can manage to deal with its tremendous flow of information, based primarily on 
unstructured text fields. The aim of this study was to develop an automated system allowing to code ADRs from 
patient reports. Our system was based on a knowledge base about drugs, enriched by supervised machine learning 
(ML) models trained on patients reporting data. To train our models, we selected all cases of ADRs reported by 
patients to a French Pharmacovigilance Centre through a national web- portal between March 2017 and March 2019 
(n = 2,058 reports). We tested both conventional ML models and deep- learning models. We performed an external 
validation using a dataset constituted of a random sample of ADRs reported to the Marseille Pharmacovigilance 
Centre over the same period (n = 187). Here, we show that regarding area under the curve (AUC) and F- measure, the 
best model to identify ADRs was gradient boosting trees (LGBM), with an AUC of 0.93 (0.92– 0.94) and F- measure 
of 0.72 (0.68– 0.75). This model was run for external validation showing an AUC of 0.91 and a F- measure of 0.58. 
We evaluated an artificial intelligence pipeline that was found able to learn how to identify correctly ADRs from 
unstructured data. This result allowed us to start a new study using more data to further improve our performance 
and offer a tool that is useful in practice to efficiently manage drug safety information.
Over the last decades, the amount of healthcare data available has 
dramatically increased. This phenomenon started with the arrival 
of electronic health records and the vast amounts of related clinical 
data.1,2 More recently, health data have been enriched by patients 
themselves using connected tools or digital platforms. These data 
should be more and more numerous and in increasingly varied and 
often unstructured formats.3,4 The corresponding challenge is to 
find novel pathways to manage heterogeneous and often unstruc-
tured healthcare information, such as texts or images. Artificial 
intelligence (AI) methods appear promising in this perspective. 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 The use of artificial intelligence (AI) to facilitate the man-
agement of adverse drug reaction (ADR) reports is a research 
area that has become a priority in recent years.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Which machine learning methods are the most efficient to 
respond to this topic?
WHAT DOES THIS STUDY ADD TO OUR KNOW-  
LEDGE?
 An AI pipeline using a knowledge database and gradi-
ent boosting trees that was found able to learn to correctly 
identify ADRs from patient reports with unstructured  
data.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 The system presented here will be deployed nation-
ally in France to strengthen the coronavirus disease 2019 
(COVID- 19) vaccination campaign pharmacovigilance.
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No consensual definition of AI actually exists; the University of 
Cambridge defines it as “the study of how to produce machines 
that have some of the qualities that the human mind has, such as 
the ability to understand language, recognize pictures, solve prob-
lems, and learn.”5 Contextualizing AI to healthcare unstructured 
data, it could be conceived as the combination of semantic infor-
mation (SI) and machine learning (ML) to perform data analysis. 
SI allows users to add meaning to data through ontologies and 
knowledge databases,2 therefore mimicking the theoretical learn-
ing patterns of a human being, whereas ML provides potentiality 
for new assumptions by aggregating information compounded 
from existing knowledge.6 Taken together, SI and ML bring ma-
chines one step closer to the way human beings manage and learn 
from information. The combination of SI and ML has already 
shown interesting results in the field of drug identification.7
Beyond medical imaging, all medical specialties could benefit 
from these technologies. This is especially true for pharmacovig-
ilance, which could evolve considerably in the coming years. Once 
marketed, medicinal products need to be continuously monitored 
in real- world settings for their use, effectiveness, and safety, the latter 
activity corresponding to pharmacovigilance. Pharmacovigilance 
activities cover the detection, assessment, understanding, and pre-
vention of adverse drug reactions (ADRs),8 which constitute one 
of the main causes of death in developed countries9 and represent a 
considerable economic burden with preventable ADRs costing up 
to $3.5 billion yearly in the United States.10,11 Moreover, according 
to the literature, 5– 6.5% of all hospital admissions could be related 
to ADRs.12
Drug safety evaluation requires monitoring and analyzing a huge 
amount of information, which can be dispersed in various sources, 
such as scientific articles, structured or unstructured health data, 
ADR reporting, or social networks. In many countries, when a 
healthcare professional or a patient wishes to report an ADR, she/
he can fill an online reporting form including structured and un-
structured data. These forms are later processed by pharmacovigi-
lance professionals who thus have to cope with the management of 
large amounts of unstructured data. Specifically, the identification 
of the reported ADRs and the evaluation of their seriousness can 
be very time- consuming from the free- text entered in these report 
forms. This raises two important concerns. First the importance of 
the resources it mobilizes could be detrimental to other pharma-
covigilance activities. Second, even essential, the standardization of 
this process appears unlikely among different teams and individ-
uals, with a risk of heterogeneously coding.13 Both these aspects 
are deleterious in terms of public health by limiting the ability to 
detect new safety signals. The current context of pharmacovigi-
lance because patients can report ADRs themselves is detailed in 
Supplemental Information  1 Text file  S1. The development of 
tools allowing to automatically process ADRs is currently the ob-
ject of intensive research and efforts, both from public and private 
entities.14 When originated from industries, these developments 
appear to be mostly restricted to their sole products.15
The underlying assumption of the present work is that a global 
knowledge database on drugs, enriched by supervised ML mod-
els trained on reporting data, could allow setting up a universal 
tool for preprocessing free text reported ADRs. This tool would 
increase efficiency in dealing with such information and improve 
capacities in drug surveillance.
AIMS
We aimed to develop an automated system allowing to code ADRs 
and their seriousness from patients’ reports free text through the 
identification and validation of the best AI pipeline. To do so, we 
defined a global pipeline from document parsing and features ex-
traction to ML model selection.
METHODS
Data collection
We selected all cases of ADRs reported by patients to Bordeaux 
Pharmacovigilance Centre through the French national web- portal be-
tween March 1, 2017, and February 28, 2019, for a total of 2,058 report 
forms. For each of these, the report form containing the free text filled by 
the patient was obtained together with the expert annotation and cod-
ing realized within the pharmacovigilance center. The coding of ADR 
was realized using the MedDRA standardized medical terminology de-
veloped by the International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use.16 MedDRA has 
been translated and is maintained in several different languages that 
allow interoperability between data from different countries. There are 
five levels to the MedDRA hierarchy, arranged from the very general to 
the very specific. Level four “Preferred Terms (PTs)” is recommended for 
the coding; 24,313 PTs are available in the terminology MedDRA 23.0 
that correspond to single concepts for symptoms, signs, disease diagno-
ses, therapeutic indications, investigations, surgical or medical proce-
dures, and medical, social, or family history characteristics. The ADRs 
coded by experts in PTs were used as a gold standard to learn and to eval-
uate the performances of each AI pipeline.
Training and validation set
These coded ADRs were used to train and validate ML algorithms for 
the identification of ADRs and ADR seriousness from the patient report- 
forms: 90% of cases (n = 1,852) were used for the train set and 10% (n = 
206) for the internal validation set (test set). We have kept 90% of the 
data for the train set to maximize our learning abilities. We tested the ro-
bustness of the best performing model on this internal dataset through an 
external validation on a 10% sample of ADRs reported by patients to the 
Marseille Pharmacovigilance Centre over the same period (n = 187). The 
used dataset included in total 10,675 reported potential ADRs for the 
learning set (train set + test set) and 407 for the external validation set.
Data extraction and preprocessing
The dataset we were provided with for this study is composed of tables 
in PDF forms containing several fields of interest. The very first step was 
to extract the text from these PDF files preserving their structure. To do 
so we used the Python library Camelot.17 The most informative section 
of the report forms was the description of the adverse events written by 
the patients. We performed basic text processing on the raw data, such as 
accents and punctuation removal, case lowering, and stemming. These 
transformations are useful to reduce noise and to limit the size of the 
vocabulary, specifically when we deal with small datasets.
Some other fields can be turned into structured features represented as:
• Integers: age, body mass index as a summary feature of weight 
and size
• Booleans: sex and one- hot representation of drugs
These additional features make it possible to take into account the pa-
tient’s specificities and treatments.
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Model- specific data formatting
Once the data extraction and text preprocessing steps are performed, we 
have to arrange the data in a format specific to the ML model we use 
for the prediction task. Most conventional ML models need numerical 
feature vectors as inputs. Consequently, we have to vectorize the adverse 
event description text. For that, we used the term frequency— inverse 
document frequency (TF- IDF) method.18 The final features vector is ob-
tained expanding TF- IDF vector with the additional features (age, sex, 
body mass index, and drugs).
The recurrent long- short- term- memory (LSTM) neural network 
we included in this study needs to be fed with word index sequences so 
a slightly different data formatting is applied. This is also the case for 
FastText and its variants (ExtremeText), which is directly provided with 
the preprocessed text.19
Identification of ADR terms and ADR seriousness
Technically, the identification of ADRs in free text is a text classifica-
tion problem that can be solved using Natural Language Processing in a 
global AI pipeline, including a knowledge base about drugs (Figure 1). 
Definition of ADR seriousness results from a worldwide consensus 
with defined criteria, the use of which is mandatory for regulators and 
pharmaceutical companies.20 To be serious, an ADR needs resulting in 
death, life- threatening, hospitalization (or prolongation of existing hos-
pitalization), persistent or significant disability or incapacity, congenital 
abnormalities/birth defect, or another significant medical event. The 
assessment of these criteria needs considering information about ADRs, 
patients’ characteristics, and treatments. Ultimately, this task leads to a 
binary classification decision resulting from the integration of heteroge-
neous information.
Models used for the benchmark
We wanted to compare various ML models usually used for text classi-
fication from the simple logistic regression to the more complex LSTM 
recurrent neural net.
Conventional ML models. We have evaluated four classical ML mod-
els: Logistic regression21,22 and Support Vector Machine (SVM),22,23 
Random Forests,24 and Gradient Boosting.25,26 None of these model 
implementations, except Random Forests, natively accepts multilabel 
classification. To work around this problem, we used the One Versus 
Rest strategy in which each modality (here MedDRA term) to predict is 
treated independently from the others and we train one model per mo-
dality, each model being a binary classifier. See for instance for an appli-
cation to the SVM algorithm.27
Gradient boosting used in this study was a gradient- boosted trees 
method. Recent gradient- boosted trees methods, such as XGBOOST28 
or LGBM,29 provide generally state- of- the- art performance on various 
classification and regression ML problems. We chose the widely used 
python lightGBM29 library for its remarkable performance in terms 
of accuracy as well as computing speed. The main difference between 
lightGBM and the other tree- based gradient boosting methods consists 
in the fact that the binary decision trees grow at the leaf level instead, 
whereas in algorithms, such as XGBOOST, they grow at the depth level 
(each leaf of the same depth level splits at the same time). This leaf level 
split provides a better adaptability and thus a better fit to the dataset.
FastText. FastText is an open- source method and python library for 
words representation and text classification.30 The classification algo-
rithm built on top of this representation method is a multinomial logistic 
Figure 1 Artificial intelligence pipeline to identify and code an adverse drug reactions (ADRs) from free text using MedDRA terminology. (a) 
Patient sends an ADR report form with clinical information. (b) Text cleaning and extraction of relevant information. (c) Matching MedDRA 
terms into the case reports using knowledge graph. (d) Data formatting for our machine learning (ML) models. Conventional ML: logit, random 
forest (RF), support- vector machine (SVM) and light gradient boosting machine (LightGBM or LGBM). Neural networks and deep learning 
models: FastText, long short- term memory recurrent neural network (LSTM) and convolutional neural network (CNN). (e) Training ML models 
on 90% of our dataset (train set) and then computing evaluation metrics on the remaining 10% (test set). (f) Selection of the best ML model 
regarding area under the curve (AUC) and F- measure.
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regression.31 We trained the word embedding on the Synapse dataset 
composed of 260 MB of text dealing with medical topics extracted from 
French reference sources. This word embedding was used by the FastText 
classification model as well as the deep learning models as embedding 
layers. In this study, we used extremeText, which is an extension of 
FastText. It implements loss functions— like probabilistic label trees— 
well adapted for extreme classification tasks (i.e., classification tasks with 
a large amount of classes).
Deep learning models. Deep learning is a subset of ML methods gath-
ering multilayer neural networks.32 Deep learning methods are generally 
better than conventional methods to process complex data and large 
datasets. Two types of deep learning models were used for the study: 
Convolutional Neural Nets (CNN)33 and LSTM34 (Figure S1).
Regular expressions and hybrid models. A very simple and straight-
forward way to tag the case reports with MedDRA concepts is to look 
for their labels directly in the description text. A well- known limitation 
of this kind of approach is the need for a rich dictionary of synonyms as 
there are often several ways to express the same concept. Working with 
semantic resources like MedDRA is a great plus as the terminology pro-
vides us with— in addition to the PTs— several alternative labels for each 
concept (called Lower Level Terms (LLTs)).
We used regular expression (RegEx) after basic text preprocessing 
(accents removal, case lowering, and stemming) to match MedDRA 
terms into the case reports. This processing method was used on both 
the MedDRA labels and the narrative itself. On the one hand, we used 
this RegEx engine as a baseline for our ML models’ benchmark; on the 
other hand, we built hybrid methods combining ML models and RegEx.
We do not expect patients to use terms that could exactly fit with a 
technical terminology, such as MedDRA. However, we can suppose that 
the RegEx approach allows the system to detect the rarer ADRs that are 
not present in the training dataset and for which ML techniques would 
not be efficient at all.
Hybrid models combine the RegEx approach and the ML models 
described above. There are several ways to aggregate predictions from 
several models. Here, we chose to average both vectors to build the 
final predictions, which is equivalent to methods used in bagging (for 
instance, random forests). Notice that due to the deterministic nature 
of regular expressions, the RegEx engine outputs binary vectors (0 or 1) 
whereas ML models provide scores between 0 and 1.
Assessment of model performances and tuning strategy
To identify ADRs and to determine ADR seriousness, each model was 
evaluated according to receiver operating characteristic (ROC) curve/
area under the curve (AUC) and F- measure (harmonic mean of the pre-
cision and recall).35
We choose to select the decision threshold that maximizes the F- 
measure. Providing reliable evaluation metrics is essential to compare 
model performances. We used 1,000 bootstrap train- test samples to com-
pute 95% confidence intervals for the evaluation metrics of each model. 
Some models, like random forests, gradient boosting, or neural networks, 
need hyper parameters tuning. For this, we used a classical grid search 
strategy on a dedicated train- test tuning split.
Overfitting and validation
Overfitting is more likely with nonparametric and nonlinear models that 
have more flexibility when learning a target function. The best solution 
to control the overfitting of an ML model is to perform an external val-
idation on independent data (external validation). In general, but even 
more for relatively small datasets, internal validation of prediction mod-
els by bootstrap techniques may not be sufficient and indicative for the 
model’s performance in future data. Our internal validation was carried 
out on 10% of Bordeaux dataset: 206 cases. Our external validation was 
carried out on 10% of cases declared to the CRPV of Marseille during 
the same period: 187 cases. Moreover, the drug distribution of these 187 
cases differed from the Bordeaux dataset and these cases were analyzed 
by different experts, which allows us to have a better estimate of the 
transposability of our system.
Programming
Concerning the model implementations, we used the python libraries 
scikit- learn and lgbm (gradient boosting) for the conventional ML mod-
els, keras (with Tensorflow backend) for the LSTM and CNN models 
and FastText + ExtremeText for the FastText model. The models were 
trained on an Intel Core i7 processor with 16 GB RAM.
Example code for LGBM (ML model with best performance) and for 
LGBM + regex are provided on the following git repository: https://
github.com/louis letin ier/MAITAI.git.
For more information about data management or our algorithms, you 
can contact the corresponding author at the email address indicated on 
the first page.
RESULTS
Dataset characteristics and representativeness
Patients who reported ADRs to the Bordeaux Centre were mostly 
women (88%) of median age 52 years (interquartile range (IQR): 
40– 62); 28% of reports mentioned serious ADRs. Altogether, 
11,591 potential ADRs were reported in the 2,058 forms (median: 
5 ADRs per report; IQR: 3– 7). After coding by experts, they were 
found to correspond to 593 distinct ADR terms (MedDRA PTs). 
Overall, 2,396 drugs were mentioned; Levothyrox (levothyroxin) 
was the main represented (n = 1,623, 68%). We stratified the 10% 
random sampling of the Marseille reports for the representation 
of levothyroxine (10%) to ensure a wider variety of cases would 
be considered for external validation. Without stratification, the 
Marseille reports included a proportion of levothyroxine cases 
comparable to Bordeaux due to the “Levothyrox crisis” detailed 
in Supplemental Information S1. After this, 187 reports from 
Marseille were selected, 44% of which were serious. They con-
cerned mostly women (74%); median age was of 44 years (IQR: 
28– 60). The reports mentioned 549 potential ADRs (median: 2 
ADRs per report, IQR: 1– 4) corresponding to 199 distinct PTs, 
and 201 drugs. The most frequent PTs for each center are listed 
in Table S1.
Owing to the size of the dataset, the training and the internal 
validation were performed considering PTs with at least 10 oc-
currences in the Bordeaux dataset, which led to consider 10,675 
potential ADRs, and 125 distinct PTs in this dataset. The exter-
nal validation focused on PTs present in the learning set, which 
led to consider 407 potential ADRs and 85 distinct PTs from the 
Marseille Centre reports in the validation set. Practically, the 125 
PTs included in our dataset corresponded to 64.6% of the 393,407 
ADRs entered in the BNPV for the period, and the 85 PTs in our 
external validation dataset corresponded to 58.3% of those. This 
guaranteed a strong representativeness of the BNPV in our dataset 
(Figure S2).
ML models performance to identify ADRs
Regarding AUC and F- measure obtained during internal valida-
tion, the model presenting the highest performance for automated 
coding of potential ADRs from patients’ reports free text was 
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LGBM (AUC = 0.93, 95% confidence interval (CI) 0.92– 0.94 
and F- measure 0.72, 95% CI 0.68– 0.75; Figure  2a,b). Among 
other models, logit (AUC = 0.91, 95% CI 0.89– 0.92); F- measure 
0.58, 95% CI 0.55– 0.62), FastText (AUC = 0.89, 95% CI 0.87– 
0.91); F- measure (0.55, 95% CI 0.51– 0.59), and LSTM (AUC = 
0.86, 95% CI 0.88– 0.89); F- measure (0.35, 95% CI 0.43– 0.47) 
showed the highest performances. The hybrid LGBM with se-
mantic approach model showed performances close to those of 
LGBM alone (AUC 0.94, 95% CI 0.93– 0.95); F- measure (0.71, 
95% CI 0.68– 0.74).
Contrary to ML models that need a minimal occurrences num-
ber to be able to detect correctly a MedDRA term, the RegEx en-
gine performances do not depend on the frequency of the terms 
and it will be able to detect even rare ADRs that were not selected 
among the 125 PTs on which we focused. However, for the sake 
of simplicity and to be able to compare models that include or not 
Figure 2 Performances of different machine learning models for the identification of adverse drug reaction from patient reports. (a) 
Performances of machine learning (ML) models in terms of receiver operating characteristic (ROC) curve and area under the curve (AUC) on 
the intern validation set. (b) Performances of ML models in terms of F- measure (F1) on the internal validation set). CNN, convolutional neural 
network; SVM, support- vector machine.
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RegEx, we limited the evaluation of RegEx and hybrid models to 
the 125 most frequent PTs.
The best performing model, LGBM, was run for external valida-
tion showing an AUC of 0.91 and a F- measure of 0.58; the limited 
validation set size did not allow computing CIs.
Finally, we compared the results of the best performing model 
only trained on text features and the same model with text and 
structured features. The use of the structured features resulted in 
a slight performance improvement from 0.69 to 0.72 F- measure.
The overall performance of all models in internal validation 
and performance of the LGBM in external validation are detailed 
in Table  1. The parameters studied were ROC curve AUC, F- 
measure, true negatives (TNs), true positives (TPs), false negatives 
(FNs), and false positives (FPs).
ML models performance for ADR seriousness determination
Regarding AUC and F- measure, the 4 conventional ML mod-
els tested showed similar performance with AUC close to 0.75 
(Figure  3a) and F- measure close to 0.60 (Figure  3b). Neural 
network models were unable to fit in the dataset effectively. As 
ADR seriousness determination is more complex than ADR iden-
tification, it is possible that this relates to the limited size of our 
learning set. Overall performance of conventional ML models to 
determine ADR seriousness are presented in Table S2.
DISCUSSION
Our study showed that an AI pipeline using a knowledge database 
to structure free text data and a ML model to learn ADR coding 
from human expertise could allow for automatic identification 
of a large proportion of the ADRs described in patients’ report 
forms unstructured data. The best performing AI pipeline using 
LGBM (gradient boosting) showed interesting results with an 
AUC of 0.93 and an F- measure of 0.72. More concretely, from the 
used test set comprising 1,061 ADRs, our system succeeded in cor-
rectly identifying and coding 703 ADRs, and incorrectly spotted 
or coded 190 others.
The performances obtained for the automated determination of 
the ADR seriousness task were lower; enlarging the experiment to 
a larger set could allow improving these. Other teams, academic 
or industrial, are currently also working on this latter aspect using 
ML models disregarding the aspect of ADR identification from 
free text.36,37
For ADR identification, we found a relative discrepancy be-
tween AUC and F- measure, highlighting how these metrics differ 
in considering a classifier’s performance. In the commonly used 
ROC curve/AUC, TP and the FP rates are considered of similar 
importance, which might present limitations for the evaluation of 
a classifier especially in the case of unbalanced data.38 AUC can 
indeed present with very high overall values if the modality “ab-
sence of ADR” is dominant in the dataset and is related to a very 
high level of specificity, even the sensitivity of the model is low. 
The F- measure conversely provides a single score that balances 
both the aspects of positive predictive value (PPV) and sensi-
tivity in just one score and is thus not affected by the predomi-
nance of a modality in the dataset. On the other hand, the main 
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sensitivity, which in some circumstances might not correspond 
to the clinical needs of the tool being evaluated.35 The results we 
present highlights the importance of using both measures when 
studying the performance of ML, especially when dealing with 
unbalanced data, such as health data.39 Indeed, the comparison of 
our ML models shows that they all retain an AUC > 0.8 despite 
very average performance for some if we look at the TP, FP, or 
FN. This is explained by these models remaining very efficient for 
TN (Table  1). Moreover, being this a first study, it seems to us 
more appropriate global performance parameters, such as AUC 
and F- measure, than practical parameters, such as sensitivity or 
specificity.
The external validation strengthened the validity of our results, 
allowing us to determine how the model performances would 
transfer to new users and new patients.40 In our results, the per-
formances obtained were lowered during the external validation. 
Because the model was trained on data from a single center, this 
was, however, expected and should be improved by enlarging the 
learning to other centers. Similarly, the lower performances of the 
models in determining ADR seriousness, a more complex task in-
volving numerous parameters, could be improved if training was 
performed on a larger dataset.
The use of real- life, expert- annotated data is the most import-
ant strength of our study. In contrast to simulation studies, it 
Figure 3 Performances of different machine learning models for the determination of adverse drug reaction seriousness from patient reports. 
(a) Performances of machine learning (ML) models in terms of receiver operating characteristic (ROC) curve and area under the curve (AUC) 
on the intern validation set. (b) Performances of ML models in terms of F- measure (F1) on the internal validation set). SVM, support- vector 
machine.
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demonstrates the concrete capacities of the AI pipeline to classify 
ADRs from unstructured textual data. Its performance could, 
however, consequently depend on peculiarities in the data and the 
transferability of the system to other settings (especially other lan-
guages) should be studied. As the overall pipeline we propose is en-
tirely transposable to English and other languages with comparable 
structures, this should theoretically not constitute an issue. Medical 
concepts, drug names, and the MedDRA classification of ADRs in-
deed benefit from multilingual reference systems, and the semantic 
approach based on a knowledge base proposed here makes it pos-
sible to link identical concepts expressed in different languages.41
The main limitation of our study is the limited size of the data-
sets used. ML methods, especially deep learning ones, require a 
large amount of data.42 One of the difficulties when dealing with 
textual data is the ability to differentiate between sentences almost 
similar in form but very different in meaning, for instance, because 
of a negation. Deep learning is theoretically the most adequate 
method to overcome this32,43 but it requires having learned enough 
about these complex situations to identify them and determine 
new ones afterward.
Attention- based transformer architectures, such as BERT and 
its numerous variants, are showing very promising results and seem 
to be the best performing methods for this kind of task.44 However, 
we did not find models pretrained on French convenient biomed-
ical datasets and our dataset was too small to consider fine- tuning 
a BERT model so we did not include these models into the study. 
With more data available, it will be a good perspective to improve 
results obtained in the current work.
In larger studies, the model ranking regarding learning capac-
ities could thus change.45 However, even using a limited data-
set, the performance obtained was already valuable. This could 
be due both to the quality of the expert- annotated data and to 
our semantic approach, which optimizes their understanding. 
However, the annotations we used to train the models and eval-
uate their performances were made manually. Moreover, due 
to the high complexity of the MedDRA terminology there is 
a high variability in the human ADR annotation process. This 
leads to a not insignificant noise in the dataset and hard to as-
sess model errors. We did not perform any measurements of this 
inter- annotator variability in this study as the necessary quali-
fied human resources were not available. However, we consider 
doing it as future work.
The results of this study are encouraging. On their basis, we will 
extend this learning to all pharmacovigilance French centers, which 
should enable to train our models on ~ 20,000 expert- annotated 
patient reports. We are also working to strengthen our semantic 
approach by taking into account textual data that correspond to a 
therapeutic indication and not to an adverse event. This will limit 
our FPs by excluding therapeutic indications.
The results of this preliminary study made it possible to launch 
the second phase of the study at the national level with 30 phar-
macovigilance centers. The improvement in performance expected 
at the end of this second phase should make it possible to set up 
a new pharmacovigilance system allowing pharmacologists to save 
precious time. Indeed, this system will allow the ADR reports to 
be sorted by seriousness and by adverse events, which will allow 
pharmacologists to focus on the most serious cases or concerning 
unexpected adverse effects.
This new system is scheduled to be deployed in 2021 to facili-
tate pharmacovigilance of coronavirus disease 2019 (COVID- 19) 
vaccines. The current French pharmacovigilance pipeline and the 
one that could be deployed after implementation are represented 
in Figure S3.
CONCLUSION
We elaborated an AI pipeline using a knowledge database and 
gradient boosting trees that was found able to learn to correctly 
identify ADRs from patient reports with unstructured data. If 
already interesting, the performance obtained can still be im-
proved, especially for ADR seriousness determination, which will 
be intended using wider and more heterogeneous datasets. Such a 
system would allow answering the increasing needs of automated 
pharmacovigilance systems for the processing of ADR reporting.
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